motilin and Peritoneal-Neoplasms

motilin has been researched along with Peritoneal-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for motilin and Peritoneal-Neoplasms

Article	Year
[Results of treatment of paralytic ileus caused by diffuse intra-abdominal metastasis with motilin. A pilot study of 25 patients]. Medizinische Klinik (Munich, Germany : 1983), 1991, Oct-15, Volume: 86, Issue:10 In a pilot-study 25 patients presenting with a paralytic ileus due to diffuse intraabdominal metastases were treated with motilin. There were 16 male (64%) and nine female (36%) patients. Gastric cancer was the most frequent cause (40%), followed by pancreatic (36%), and colorectal (20%) cancer. 36% had received a postoperative chemotherapy before commencing the motilin-scheme. In 92% motilin therapy was started within 48 hours after the diagnosis of paralytic ileus. There were no serious side-effects of motilin therapy. In approximately 80% the pretherapeutic state was improved. Thus, it seems worthwhile to investigate the influence of motilin on paralytic ileus in incurable cancer patients in a prospective controlled trial. Topics: Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Intestinal Pseudo-Obstruction; Male; Motilin; Palliative Care; Peritoneal Neoplasms; Postoperative Complications	1991

Article

Year

[Results of treatment of paralytic ileus caused by diffuse intra-abdominal metastasis with motilin. A pilot study of 25 patients].

Medizinische Klinik (Munich, Germany : 1983), 1991, Oct-15, Volume: 86, Issue:10

In a pilot-study 25 patients presenting with a paralytic ileus due to diffuse intraabdominal metastases were treated with motilin. There were 16 male (64%) and nine female (36%) patients. Gastric cancer was the most frequent cause (40%), followed by pancreatic (36%), and colorectal (20%) cancer. 36% had received a postoperative chemotherapy before commencing the motilin-scheme. In 92% motilin therapy was started within 48 hours after the diagnosis of paralytic ileus. There were no serious side-effects of motilin therapy. In approximately 80% the pretherapeutic state was improved. Thus, it seems worthwhile to investigate the influence of motilin on paralytic ileus in incurable cancer patients in a prospective controlled trial.

Topics: Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Intestinal Pseudo-Obstruction; Male; Motilin; Palliative Care; Peritoneal Neoplasms; Postoperative Complications

1991